Recently, synergistic effects have been described in TNBC using CDC25 inhibitors plus WEE1 or PI3K inhibitors [64], as well as a synthetic lethal interaction between RB1-deficiency and Aurora Kinase A or B inhibitors in SCLC or TNBC [65, 66]. This evidence concerns the gene AURKA and small cell lung carcinoma.